Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Checkpoint kinase 1 (CHK1) mRNA 3' untranslated region (UTR) is a critical regulatory segment of the CHK1 transcript that governs the expression of the CHK1 protein (UniProt P20823). CHK1 is a central coordinator of the DNA damage response, ensuring cell cycle arrest and DNA repair following genomic stress (Smith et al., 2010, PubMed: 20512122). The 3' UTR contains specific binding sites for various microRNAs, such as miR-195 and miR-497, which act as natural tumor suppressors by downregulating CHK1 levels (Wang et al., 2011, PubMed: 21571558). In many cancers, the loss of these regulatory microRNAs leads to CHK1 overexpression, contributing to tumor survival and resistance to DNA-damaging therapies (Xie et al., 2015, PubMed: 26315448). Consequently, the CHK1 mRNA 3' UTR is an emerging therapeutic target for RNA-based interventions, including microRNA mimics and antisense oligonucleotides. By targeting this region, researchers aim to suppress CHK1 expression, thereby sensitizing cancer cells to chemotherapy and radiotherapy (Itakura et al., 2013, PubMed: 23467440). This approach offers a post-transcriptional alternative to small-molecule CHK1 inhibitors, potentially providing different selectivity and safety profiles.
Binding of microRNA mimics or antisense agents to the 3' UTR sequence to induce mRNA degradation or translational repression, thereby reducing CHK1 protein levels.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Checkpoint kinase 1 mRNA 3' untranslated region (CHK1 mRNA 3' UTR).